Our previous work showed that tp53 loss specifically enhanced invasion and metastasis in vivo (Ignatius et al., 2018), suggesting that while TP53 is shown to suppress tumor progression by multiple mechanisms depending on tumor type, loss of TP53 in human ERMS may influence clinical outcomes through a combination of increased tumor cell proliferation, invasion, and metastasis (Ignatius et al., 2018). Here, TP53 is linked to neoplasm.